84.83 USD
▲+0.85+1.01%
盘后 83.64 -1.40%
2026-11-19
市值
$4.72B
市盈率
—
EPS
-3.91
股息率
—
52 周区间
35.84 – 117.88
成交量
896.83K
Beta
0.26
目标价
139.25
52W 低 35.8452W 高 117.88
价格走势
公司简介
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell functio...